<DOC>
	<DOCNO>NCT00797953</DOCNO>
	<brief_summary>The purpose study determine anti-angina effect dose response T89 , 2-herb botanical drug product , patient chronic stable angina pectoris United States .</brief_summary>
	<brief_title>Phase II Multi-Center Study T89 Treat Chronic Stable Angina</brief_title>
	<detailed_description>T89 modernize industrialized version traditional Chinese herbal medicine . T89 approve market drug , treatment chronic stable angina pectoris due coronary heart disease , State Food Drug Administration ( SFDA ) China 1993 . There 2 billion dos prescribe use , 10,000,000 subject , short long-term administration worldwide . The product also market , drug , Russia , South Korea , Mongolia , Singapore , Vietnam , South Africa . The current study determine anti-angina effect dose response T89 patient chronic stable angina pectoris United States . T89 consist Danshen ( Radix Salviae Miltiorrhizae , RSM ) Sanqi ( Radix Notoginseng , RN ) active constitutes , use Borneol transport enhancer .</detailed_description>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<criteria>1 . Patient must age 18 80 year . 2 . Females childbearing potential must negative pregnancy test , breast feeding establish method contraception investigator 's opinion acceptable . Females must agree remain established method contraception participation study . 3 . Evidence coronary artery disease consist welldocumented medical history ( 3 month prior enrollment ) myocardial infarction significant coronary artery disease noninvasive angiographic confirmation . 4 . Symptoms support diagnosis chronic angina and/or history abnormal exercise response limit angina and/or electrocardiograph ( ECG ) change . 5 . Moderate angina pectoris ( Class II Class III , Grading Angina Pectoris Canadian Cardiovascular Society Classification System ) 6 . Naive patient patient 's Total Exercise Duration ( TED ) 3 7 minute ETT Standard Bruce Protocol , difference TED must 15 % two screen examination day 7 day 0 7 . All antiangina regimen ( except shortacting nitroglycerin , one betablocker calcium channel blocker ) , warfarin oral anticoagulant use prior initial visit discontinue . 8 . Patient must understand willing , able likely comply study procedure restriction comprehends verbal rating scale diary card . 9 . Patient must able give voluntary write informed consent . 1 . With contraindication perform treadmill Exercise Tolerance Test ( ETT ) . 2 . Preexercise STsegment depression least 1 mm lead , leave bundle branch block , digoxin therapy , Left Ventricular Hypertrophy ( LVH ) WolffParkinsonWhite ( WPW ) syndrome factor could interfere exercise electrocardiograph interpretation . 3 . Clinically significant arrhythmia atrioventricular conduction block great first degree . 4 . Clinically significant comorbidities , include hepatic renal dysfunction , pulmonary hypertension , chronic obstructive pulmonary disease , history cerebral hemorrhage , seizure disorder require anticonvulsant medication . 5 . History congestive heart failure , unstable angina , severe valvular disease , severe hypertension , severe anemia , suspect know dissect aneurysm , acute myocarditis pericarditis , thrombophlebitis pulmonary embolism recent myocardial infarction within three month study entry . 6 . History bleed diathesis , warfarin . 7 . Implanted pacemaker . 8 . Aspirin and/or statin start less 14 day prior sign inform consent . 9 . Pregnancy lactation . 10 . Inability discontinue exist chronic nitrate regimen ( e.g . long act nitroglycerin ) allow shortacting nitroglycerin one betablocker calcium channel blocker . 11 . Clinical trials/experimental medication : Participation clinical trial receipt investigational drug within 90 day prior initial visit . Those patient unable , opinion investigator , comply fully trial requirement . Previous participation study . 12 . Substance abuse . Patients recent history ( within last 2 year ) alcoholism know drug dependence . 13 . Patient family member relative study site staff .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Angina Pectoris Treatment</keyword>
</DOC>